Key takeaways:
Mounjaro (tirzepatide) and metformin are medications that are FDA approved to treat Type 2 diabetes. It’s generally safe for most people to combine them if needed to reach their diabetes treatment goals.
Taking Mounjaro and metformin together can be more effective at lowering blood glucose (sugar) than taking either one alone. You may also experience weight loss while taking both medications.
Digestive-related side effects, such as nausea and diarrhea, are common with both Mounjaro and metformin. If you do experience these side effects, your symptoms will likely improve as your body adjusts to the medications.
Metformin is the most prescribed diabetes medication in the U.S. It’s also one of the safest and most effective medications for diabetes on the market. Because of this, it’s considered a first-choice treatment for many adults and children with Type 2 diabetes.
But what are your options if you’re taking metformin and your blood glucose (sugar) levels aren’t staying in your target range? It’s common to take more than one medication to help meet diabetes treatment goals. And there are many oral and injectable options that can be safely combined with metformin.
Mounjaro (tirzepatide) is an injectable Type 2 diabetes medication that’s grown in popularity over the past few years. But can you take Mounjaro and metformin together? In short, yes. And the combination can be beneficial for many people with Type 2 diabetes.
Save every month on GLP-1 meds with GoodRx
Save an average of $235 on FDA-approved GLP-1s like Ozempic and Zepbound.
Both Mounjaro and metformin are FDA approved to help lower blood glucose levels for people with Type 2 diabetes. They both work best when combined with a diabetes-friendly diet and regular exercise. But they are approved for use in different age groups.
Mounjaro is currently only approved for use in adults. There’s an ongoing clinical trial studying its safety and effectiveness in children as young as 10 years old. This study is expected to finish in early 2025. So Mounjaro could be approved for use in kids with Type 2 diabetes some time after that.
On the other hand, metformin is approved for use in adults and children age 10 and older. Until 2023, it was one of the only Type 2 diabetes treatments that was approved for use in kids.
Good to know: Tirzepatide, Mounjaro’s active ingredient, is also approved for chronic weight management in adults. But it’s approved for this use under a different brand name: Zepbound. Mounjaro isn’t an approved weight-loss medication.
Yes, most people can safely take Mounjaro and metformin together if needed. Though, people typically try one diabetes medication (commonly metformin) by itself first. If that doesn’t work well enough to lower blood glucose levels, then a prescriber may suggest adding a second medication, which is called combination therapy.
For people who need combination therapy, the American Diabetes Association recommends starting sooner rather than later. This can help lower the risk of diabetes-related complications in the long run.
Mounjaro may be a preferred choice if your diabetes treatment goals include losing weight. As we’ll discuss more below, Mounjaro can promote significant weight loss for many people.
One main difference between metformin and Mounjaro is the way they’re taken.
Mounjaro vs. metformin: Pharmacists review key differences between the diabetes medications Mounjaro and metformin.
Experts tips: Your hemoglobin A1C (HbA1c or A1C) helps determine your diabetes management plan. Here, experts review proven tips for lowering your A1C to help you meet your treatment goals.
What to expect: Find out how three people describe their experiences with starting treatment with Mounjaro and how they managed side effects.
Metformin is most commonly taken as oral tablets, though an oral solution is also available. Metformin comes in two forms:
An immediate-release form, which is typically taken 1-3 times daily with meals
An extended-release form, which is typically taken once a day with an evening meal
You’ll likely start with a lower metformin dosage and slowly increase it as needed to help limit side effects.
Mounjaro, on the other hand, is a once-weekly injection that’s given at home. It’s available as prefilled injection pens and single-use vials. You’ll start with the lowest Mounjaro dosage (2.5 mg once a week) and gradually raise it over several weeks. This helps to minimize side effects while your body adjusts to the medication.
The biggest benefit of taking Mounjaro and metformin together is that you may achieve lower blood glucose levels than you would taking either by itself. And over time, better glucose balance can help lower your risk of diabetes-related complications, such as nerve or kidney damage.
Mounjaro and metformin are both effective diabetes medications. They can help lower your blood glucose levels and hemoglobin A1C (HbA1c or A1C). Your A1C is your average glucose level over a 3-month period.
When taken without other diabetes medications, metformin can reduce a person’s A1C by up to 1.5%. But when Mounjaro was added to metformin in clinical trials, people experienced an additional 2% A1C reduction. Researchers also found that over 85% of trial participants using Mounjaro reached an A1C of less than 7% — a common goal for many people with Type 2 diabetes.
While neither Mounjaro nor metformin are FDA approved as weight-loss medications, losing weight is a potential side effect of both.
In fact, one of the reasons Mounjaro has made headlines is because of this potential for losing weight. Many people have lost significant weight while using it. In clinical trials, people with Type 2 diabetes that were considered overweight or obese lost up to 15% of their starting body weight after using Mounjaro for 72 weeks (about 16.5 months).
This is what led to tirzepatide, Mounjaro’s active ingredient, being approved as a weight-loss medication under the brand name Zepbound.
Metformin is generally considered a “weight neutral” medication. This means it doesn’t usually cause noticeable weight changes. But in some studies, people have experienced a modest decrease in body weight while taking it. One of these studies noted an average weight loss of 4 to 5 lbs in participants who took metformin for 1 year.
When taken separately, Mounjaro and metformin can both cause gastrointestinal (GI) side effects. So it makes sense that you may experience these side effects if you’re taking them together. Common examples include nausea or vomiting, diarrhea, and stomach pain. If you experience GI side effects, your symptoms will likely improve as your body adjusts to the medication(s).
Another potential side effect that’s listed in both Mounjaro’s and metformin’s labeling is hypoglycemia (low blood glucose). But this is extremely rare with both medications — even if you’re taking them together.
Your risk of low blood glucose may be higher if you’re also taking other diabetes medications, such as insulin and sulfonylureas. Be sure to discuss these risks with your diabetes care team. They may make dosage adjustments to one or more of your medications to help you avoid low blood glucose.
There are also rare but serious side effects that are unique to each of these medications. These include:
Lactic acidosis (metformin)
Vitamin B12 deficiency (metformin)
Inflammation of the pancreas, also called pancreatitis (Mounjaro)
Gallbladder problems (Mounjaro)
Certain thyroid cancers seen in animal studies (Mounjaro)
Keep in mind, this isn’t a list of all potential side effects for Mounjaro or metformin. Your prescriber or pharmacist can provide you with more detailed information for either medication.
Mounjaro and metformin are safe, effective medications for many people living with Type 2 diabetes. But there are situations in which one or both medications may not be right for you. For instance, if you’re already meeting your treatment goals with one diabetes medication, it’s unlikely that your prescriber will suggest you take another.
You shouldn’t take Mounjaro if:
You have a personal or family history of medullary thyroid cancer
You have a history of multiple endocrine neoplasia syndrome type 2 (MEN 2)
You’re taking a medication similar to Mounjaro, such as Ozempic (semaglutide), Victoza (liraglutide), or Trulicity (dulaglutide)
You shouldn’t take metformin if:
You have moderate-to-severe kidney disease
You’re experiencing sudden or chronic metabolic acidosis (an acid-base imbalance in the body), including diabetic ketoacidosis
If taking Mounjaro and metformin together isn’t right for you, don’t fret. There are many other options available for combination therapy. Your diabetes care team can help you find the best choice for you.
Mounjaro (tirzepatide) and metformin are both FDA approved to treat Type 2 diabetes. Most people can safely take Mounjaro and metformin together. And taking them together can be more effective at lowering blood glucose (sugar) than taking either one alone.
Many people also lose weight while taking Mounjaro and metformin. But this combination isn’t right for everyone with Type 2 diabetes. Talk to your healthcare team about whether taking Mounjaro and metformin together may be right for you.
American Diabetes Association. (n.d.). Holistic person-centered approach to T2DM management.
American Diabetes Association. (1984). Use of glucose-lowering medications in the management of type 2 diabetes.
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2024. Diabetes Care.
American Diabetes Association Professional Practice Committee. (2024). 14. Children and adolescents: Standards of care in diabetes—2024. Diabetes Care.
ClinCalc. (2021). Antidiabetic agents: Multum therapeutic class comparison, United States, 2022.
ClinicalTrials.gov. (2024). A study to evaluate tirzepatide (LY3298176) in pediatric and adolescent participants with type 2 diabetes mellitus inadequately controlled with metformin or basal insulin or both (SURPASS-PEDS). U.S. National Library of Medicine.
Eli Lilly and Company. (2024). Mounjaro - tirzepatide injection, solution [package insert]. DailyMed.
Frías, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine.
Garvey, W. T., et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet.
Quality Care Products. (2024). Metformin HCL - metformin HCL tablet [package insert].
Sanchez-Rangel, E., et al. (2017). Metformin: Clinical use in type 2 diabetes. Diabetologia.
The Diabetes Prevention Program Research Group. (2012). Long-term safety, tolerability, and weight loss associated with metformin in the diabetes prevention program outcomes study. Diabetes Care.
U.S. Food and Drug Administration. (2023). FDA approves new class of medicines to treat pediatric type 2 diabetes.